Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278513 | 0.81 | GRM5 (0.68) | GRM5HAO1ACACBNPC1RAB9A | |
| SCHEMBL4747174 | 0.77 | GRM5 (0.68) | GRM5HAO1ACACBNPC1RAB9A | |
| SCHEMBL6313587 | 0.77 | GRM5 (0.68) | GRM5HAO1ACACBNPC1RAB9A | |
| SCHEMBL6311975 | 0.77 | GRM5 (1.00) | GRM5HAO1APPACACBPDE10A | |
| SCHEMBL10236313 | 0.77 | GRM5 (0.62) | GRM5HAO1ACACBPDE10A | |
| SCHEMBL674764 | 0.75 | APP (0.77) | APPACACBNPC1RAB9AKCNH2 | |
| SCHEMBL15870993 | 0.75 | GRM5 (0.68) | GRM5HAO1ACACBFBP1PDE10A | |
| SCHEMBL10300057 | 0.75 | APP (0.77) | APPACACBNPC1RAB9AKCNH2 | |
| SCHEMBL13509098 | 0.75 | NPC1 (0.43) | GRM5APPACACBNPC1RAB9A | |
| SCHEMBL30278529 | 0.74 | GRM5 (0.40) | GRM5HAO1ACACBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021871-A2 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | GRM5 4631/4885HAO1 4294/4885APP 1367/4885 |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | GRM5 4584/4885HAO1 3632/4885APP 1228/4885 |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, CTSC | GRM5 4638/4885HAO1 4229/4885APP 1270/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | GRM5 4643/4885HAO1 4318/4885APP 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.